Table 3.

Associations between of CNOT6 rs2453176 (C >T) and lung cancer risk stratified by histologic types in all eight lung cancer GWASs from ILCCO-TRICL

Study	Overall				AD				SC
	Case	Control	OR (95% CI)	P	Case	Control	OR (95% CI)	P	Case	Control	OR (95% CI)	P
ICR	1952	5200	1.15 (1.02–1.28)	0.020	465	5200	1.38 (1.12–1.70)	0.002	611	5200	1.14 (0.95–1.38)	0.158
MDACC	1150	1134	1.25 (1.03–1.52)	0.027	619	1134	1.06 (0.92–1.47)	0.206	306	1134	1.45 (1.08–1.94)	0.013
IARC	2533	3791	1.14 (1.00–1.29)	0.053	517	2824	1.13 (0.90–1.42)	0.301	911	2968	1.18 (0.98–1.41)	0.081
NCI	5713	5736	1.10 (1.01–1.21)	0.025	1841	5736	1.17 (1.03–1.33)	0.016	1447	5736	1.04 (0.91–1.20)	0.543
Toronto	331	499	1.12 (0.76–1.63)	0.057	90	499	1.48 (0.83–2.64)	0.186	50	499	1.00 (0.44–2.25)	0.998
GLC	481	478	0.93 (0.69–1.26)	0.064	186	478	1.25 (0.86–1.83)	0.240	97	478	0.90 (0.52–1.54)	0.695
Discovery combined	12160	16838	1.13 (1.06–1.19)	4.33E-05	3818	15871	1.21 (1.11–1.32)	2.04E-05	3424	16015	1.13 (1.03–1.23)	0.009
Harvard	984	970	0.85 (0.68–1.05)	0.133	597	970	0.79 (0.62–1.01)	0.130	216	970	1.08 (0.75–1.56)	0.678
deCODE	1319	26380	1.14 (1.01–1.28)	0.032	547	26380	1.02 (0.85–1.21)	0.858	259	26380	1.11 (0.86–1.43)	0.436
Replication combined	2303	27350	1.00 (0.75–1.32)	0.098	1144	27350	0.91 (0.71–1.16)	0.449	475	27350	1.10 (0.89–1.36)	0.381
Overall	14463	44188	1.11 (1.04–1.18)	0.001	4862	43221	1.13 (1.00–1.27)	0.050	3897	43365	1.12 (1.03–1.22)	0.006

GWAS: genome-wide association study; ILCCO: International Lung Cancer Consortium; TRICL: Transdisciplinary Research in Cancer of the Lung; AD, adenocarcinoma; SC, squamous cell carcinoma; OR: odds ratio; CI: confidence interval

Homogeneity tests suggest that there is no heterogeneity between the subgroups of AD and SC in each GWAS and overall result (P > 0.05).